Loading ...

Research Study of ATG and Rituximab in Renal Transplantation

(

RESTARRT

)

ITN Protocol #:

ITN039ST

Branded Name:

RESTARRT

ClinicalTrials.Gov ID:

NCT01318915

Treatment Protocol #:

ATG / Rituximab

Therapeutic Area:

Transplantation

Current Status:

Complete

Summary:

Immunosuppression With Antithymocyte Globulin, Rituximab, Tacrolimus, Mycophenolate Mofetil and Sirolimus, Followed by Withdrawal of Immunosuppression, in Living-donor Renal Transplant Recipients

Clinical Operations Manager

ITN Biologist

ITN Biostat

ITN Clinical Trial Physician

NIAID Project Manager

Rho Scientist

PPD Lead Monitor

Study Personnel:

Protocol Chair

Michele DesMaraismdesmarais@immunetolerance.org

Work: 

415-420-4250

Protocol Chair

Bryna Burrellbburrell@immunetolerance.org

Work: 

240-235-6130

Protocol Chair

Sai Kanaparthiskanaparthi@immunetolerance.org

Work: 

(240)235-6101

Protocol Chair

Sindhu Chandran, MDschandran@immunetolerance.org

Work: 

415-610-4284

Protocol Chair

Allison Prioreallison.girouard@nih.gov

Work: 

240-627-3550

Protocol Chair

David Ikle, PhDDavid_Ikle@rhoworld.com

Work: 

919-595-6378

Protocol Chair

Jeffrey W. SmithJeffrey.Smith@ppdi.com

Work: 

1 504 810 9585